Header Logo

Connection

GABRIEL LOPEZ to Gene Expression Regulation, Neoplastic

Back to Details
This is a "connection" page, showing publications GABRIEL LOPEZ has written about Gene Expression Regulation, Neoplastic.
GABRIEL LOPEZ
Connection Strength
0.881
Gene Expression Regulation, Neoplastic
  1. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 2009 Oct 22; 4(10):e7502.
    View in: PubMed
    Score: 0.111
  2. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma. 2004 May; 45(5):979-85.
    View in: PubMed
    Score: 0.076
  3. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk Lymphoma. 1998 Jul; 30(3-4):367-79.
    View in: PubMed
    Score: 0.051
  4. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015 Jan; 235(1):25-36.
    View in: PubMed
    Score: 0.039
  5. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.
    View in: PubMed
    Score: 0.039
  6. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
    View in: PubMed
    Score: 0.035
  7. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99.
    View in: PubMed
    Score: 0.035
  8. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res. 2013 Jan 01; 19(1):170-82.
    View in: PubMed
    Score: 0.034
  9. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012 Oct; 33(10):1843-53.
    View in: PubMed
    Score: 0.033
  10. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3716-26.
    View in: PubMed
    Score: 0.031
  11. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99.
    View in: PubMed
    Score: 0.030
  12. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
    View in: PubMed
    Score: 0.026
  13. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.
    View in: PubMed
    Score: 0.025
  14. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008 Jul; 4(5):669-79.
    View in: PubMed
    Score: 0.025
  15. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007 Oct 12; 282(41):29919-26.
    View in: PubMed
    Score: 0.024
  16. Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk Lymphoma. 2003 Nov; 44(11):1979-85.
    View in: PubMed
    Score: 0.018
  17. Bcl-2-related antisense therapy. Semin Oncol. 2002 Jun; 29(3 Suppl 11):71-6.
    View in: PubMed
    Score: 0.017
  18. GRB2: a pivotal protein in signal transduction. Semin Oncol. 2001 Oct; 28(5 Suppl 16):142-7.
    View in: PubMed
    Score: 0.016
  19. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep. 1999 Mar-Apr; 6(2):257-62.
    View in: PubMed
    Score: 0.013
  20. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 1999 Feb 11; 18(6):1325-32.
    View in: PubMed
    Score: 0.013
  21. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem Biophys Res Commun. 1997 Jun 18; 235(2):383-8.
    View in: PubMed
    Score: 0.012
  22. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan; 5(1):95-108.
    View in: PubMed
    Score: 0.011
  23. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014 Dec 08; 26(6):863-879.
    View in: PubMed
    Score: 0.010
  24. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014 Dec 05; 5:5671.
    View in: PubMed
    Score: 0.010
  25. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014 May 05; 10:728.
    View in: PubMed
    Score: 0.010
  26. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014 May; 35(5):1100-9.
    View in: PubMed
    Score: 0.009
  27. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
    View in: PubMed
    Score: 0.009
  28. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20.
    View in: PubMed
    Score: 0.009
  29. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
    View in: PubMed
    Score: 0.009
  30. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.
    View in: PubMed
    Score: 0.009
  31. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171.
    View in: PubMed
    Score: 0.008
  32. Neuropilin-2 mediated ?-catenin signaling and survival in human gastro-intestinal cancer cell lines. PLoS One. 2011; 6(10):e23208.
    View in: PubMed
    Score: 0.008
  33. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
    View in: PubMed
    Score: 0.008
  34. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121.
    View in: PubMed
    Score: 0.008
  35. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011 Jun 07; 8(8):467-77.
    View in: PubMed
    Score: 0.008
  36. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011 Jun; 30(6):368-70.
    View in: PubMed
    Score: 0.008
  37. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov 12; 285(46):35462-70.
    View in: PubMed
    Score: 0.007
  38. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7.
    View in: PubMed
    Score: 0.007
  39. Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia. Trans Assoc Am Physicians. 1990; 103:236-41.
    View in: PubMed
    Score: 0.007
  40. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
    View in: PubMed
    Score: 0.007
  41. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 05; 100(5):359-72.
    View in: PubMed
    Score: 0.006
  42. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.
    View in: PubMed
    Score: 0.006
  43. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ. 1997 Oct; 8(10):1071-82.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.